SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Strategies & Market TrendsSpeculating in Takeover Targets


Previous 10 Next 10 
To: richardred who wrote (4446)5/12/2017 1:24:17 PM
From: richardred
   of 6101
 
RE-ASVI/ MNTX Well that didn't take long from my last post. I absolutely love what the board decided to do with their ASVI stake.

IMO restores much value back to the company. This with my take of straight mask cranes, and my personal take, of not being a strict constructionist (pun intended) on value stock buys.

Upon successful IPO completion. Future catalyst- Debt levels should sink as well as quarterly interest payments. A reduced debt level is also a positive selling point among potential buyers of their products. IMO This makes the IPO a future target itself. This scenario with TEX approval. This puts CAT into play as a future niche possible hypothetical buyer for ASV. IMO this move also makes MNTX a more of a speculative target. Failed TEX bidder ZOOMLION once again comes to mind. I can still see ZL being interested in the US infrastructure market. This would make it smaller, but a more affordable way to participate. It also would mostly likely not be in the selling to China political limelight like the failed TEX deal was.





Share RecommendKeepReplyMark as Last ReadRead Replies (3)


To: richardred who wrote (4449)5/15/2017 8:13:51 AM
From: richardred
   of 6101
 
A quick competitive response by Thermo-Fisher.

Thermo Fisher to buy Patheon for about $5.2 billion.

reuters.com

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (4449)5/16/2017 10:32:33 AM
From: richardred
   of 6101
 
Sold SITT # 1 weighted position in INCR today. The company's coming merger 75 million break up fee clause. Scares possible hypothetical suitors of INCR. Plus the costs associated with the merger. IMO make it near term fully valued fundamentally . Another 5% gain on top of the merger announcement gain made it to tempting to hold.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: richardred who wrote (4456)5/16/2017 11:50:51 AM
From: richardred
   of 6101
 
Added some MNTX leap calls today. Changing SITT board tracking stock from INCR to MNTX today.

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (2932)5/17/2017 8:37:37 AM
From: richardred
   of 6101
 
CL at the right price!

Colgate-Palmolive’s chief executive recently signaled he would be open to selling the company — which has grappled with sluggish demand for its toothpaste, deodorants and food products — for $100 a share, a source told The Post.

nypost.com

P.S.

>Colgate-Palmolive Co (Very Big, but never say never)

Message 27708293

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (4458)5/18/2017 10:19:11 AM
From: richardred
   of 6101
 
NEW buy today, it's been on my watch list- HUBG-Investing some proceeds from INCR.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: richardred who wrote (4453)5/18/2017 11:16:11 AM
From: richardred
   of 6101
 
Added to MNTX today.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


From: richardred5/19/2017 9:58:47 AM
   of 6101
 
New buy yesterday AVT.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: richardred who wrote (4120)5/22/2017 8:02:07 AM
From: richardred
   of 6101
 
Huntsman and Clariant nearing $14 billion merger - WSJ

Share RecommendKeepReplyMark as Last Read


To: richardred who wrote (4345)5/22/2017 10:26:54 AM
From: richardred
   of 6101
 
Darn- had this on high priority on my watch list, but never struck.
I guess I'll keep a better eye on NAII now. That wasn't as high on the list as NUTR was.


Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10